Aortic valve stenosis (AS) is the most common valvular disease in the western world. The underlying pathophysiology of AS is divided into an initiation phase resembling atherosclerosis, including lipid infiltration, oxidation, and inflammation, and a propagation phase characterized by fibrosis and calcification.
1 Even if low-density lipoprotein (LDL) cholesterol may be important in the initiation phase, lipid-lowering therapy with statins and ezetimibe has been unsuccessful in halting the disease.
2